Therapy / Class: Antibacterial / Third-Generation Cephalosporin Antibiotic plus β-lactamase inhibitor
Spectrum of Coverage:
Gram-positive bacteria (β-lactamase Producing Strains)
- Streptococcus pneumoniae
- Streptococcus pyogenes
Gram-negative bacteria (β-lactamase Producing Strains)
- Haemophilus influenzae
- Moraxella catarrhalis
- Escherichia coli
- Proteus mirabilis
- Neisseria gonorrhoeae
Mechanism of Action:
Cefixime shows bactericidal action by inhibition of bacterial cell wall synthesis. It is found to be ineffective against bacteria that produce ESBL enzymes and resistance is seen in such types of bacteria. Clavulanic acid contains a beta-lactam ring in its structure that binds in an irreversible fashion to beta-lactamases, preventing them from inactivating Cefixime. The combination of cefixime and clavulanic acid (β-lactamase inhibitor) provides a solution for treatment of bacterial infections caused by β-lactam resistant Bacteria.
Indications: (In β lactamase Resistant Infections)
- Typhoid Fever / Quinolone-Resistant Uncomplicated Typhoid Fever
- Otitis Media
- Pharyngitis & Tonsillitis
- Acute Bacterial Sinusitis
- Acute Exacerbations of Chronic Bronchitis
- Uncomplicated Urinary Tract Infection (UTI)
- Community-Acquired Pneumonia due to Haemophilus influenzae
Dosage & Administration:
Paediatric Patients (6 months or older): Dose of Cefixime is considered for treatment of all Infections 8mg/kg/day of the suspension & may be administered as a single daily dose or may be given in two divided doses, as 4mg/kg every 12 hours.
Duration of therapy: Ranges from 3 to 14 Days depending on type & severity of Infection
PEDIATRIC DOSAGE CHART | |
Patient Weight (kg) | Dose/Day (mg) |
5 to 6.2 | 50 |
6.3 to 12.5 | 100 |
12.6 to 18.8 | 150 |
18.9 to 25 | 200 |
25.1 to 31.3 | 250 |
31.4 to 37.5 | 300 |
37.6 to 43.8 | 350 |
43.9 to 50 | 400 |
HOW SUPPLIED:
METAFIX CV 100 DISPERSIBLE TABLET is available as dispersible tablet in 10 x 10 aluminum strip
References:
- Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):131-9.
- Ann Clin MicrobiolAntimicrob. 2022 May 22;21(1):20.
- J AntimicrobChemother. 2021 Oct 11;76(11):2839-2846.
Reviews
There are no reviews yet.